Reports FY22 revenue $16,000, consensus $10,000. "In 2022, we laid the groundwork to advance camlipixant, our P2X3 receptor antagonist product candidate with best-in-class potential, into late-stage development in RCC. This included interacting with regulatory officials, solidifying the CALM Phase 3 trial designs and conducting validation work on the VitaloJAK cough monitoring system – all of which allowed us to initiate CALM-1 and CALM-2 in the fourth quarter," commented Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "Looking ahead to 2023, we will remain focused on advancing our CALM Phase 3 clinical program and building out our commercial strategy, while tracking the upcoming key developments in the P2X3 receptor class."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly